Request more information or explore ordering options to bring Precise Tumor testing to your practice.
Whether you’ve heard about genetic testing before or want to learn more, we can help provide in-depth information on the test and your testing options.
Precise™ Tumor† simplifies patient care for clinicians by providing straightforward interpretations, prioritization of therapies, and the next steps specific to each patient’s genomic results.
† Precise Tumor is powered by Intermountain Precision Genomics®, a service of Intermountain® Healthcare
Precise Tumor is a pan-cancer, comprehensive laboratory test that uses state-of-the-art, next-generation sequencing to discover and target important variants within tumors. This hybrid-capture DNA- and RNA-based test detects Single-Nucleotide Variants (SNV), Insertion-Deletion Mutations (INDELs), Copy Number Variants (CNV), splice variants and fusions in solid tumors.
By using tumor testing procedures that you are familiar with in an innovative and comprehensive way, Precise Tumor testing will allow you to save time, gain confidence, and arm yourself with the information you need to help your patients.
Precise Tumor is validated for all solid tumor types and includes sequencing of over 500 genes identified as relevant to cancer treatment, as well as testing of important immunotherapy (IO) biomarkers to provide a comprehensive picture for you to formulate a treatment plan with your patients.
500+ solid tumor-related genes with broad coverage of key guidelines and clinical trials for multiple solid tumor types. (View full biomarker list)
Key Selected Biomarkers:
Provides genomic coverage necessary for accurate selection of FDA-approved targeted and IO therapies, while also evaluating many genes relevant to early phase drug development efforts that may have future clinical applications in all solid tumors.1
Validated to 98.91% Analytical Sensitivity and >99.99% Analytical Specificity with targeted exome sequencing with full coverage of all exons. Accurately measures TMB, microsatellite instability, SNVs, indels, copy-number/structural variation and gene fusions when compared to WGS and orthogonal technologies.2
Fusions and splice variants assessed via RNA analysis, which may detect more actionable fusions and splice variants, as compared to DNA tests only.3-6
Content for Precise Tumor includes key guideline biomarkers for multiple cancer types, plus current and emerging pan-cancer biomarkers, to provide you with a comprehensive picture for formulating treatment plans.
Fill out a test request form in the Myriad Genetics provider portal
Our laboratory processing staff will contact your pathology partner directly to obtain the tumor sample for Precise Tumor testing
Results will be reported in the provider portal as they become available
With Precise™ Oncology Solutions, you can receive results for comprehensive germline testing, tumor profiling and companion diagnostic options, including Precise Tumor, in one single ordering experience, getting clear, fast answers for your patients.
Precise Tumor simplifies patient care for oncologists by providing straightforward interpretations, prioritization of therapies, and the next steps specific to each patient’s genomic results.
Myriad is committed to providing patients with access to accurate and affordable genetic results through extensive coverage with most insurance plans and financial assistance programs.
Myriad believes in providing the most accurate and highest quality tests for patients. From hereditary cancer to precision medicine, our tests are designed to give providers and patients the most accurate answer possible.